Oxford BioMedica plc Management and Board change
—Appointment of new Chief Financial Officer and Company Secretary — Oxford, UK – 10 February 2012: Oxford BioMedica (“Oxford BioMedica” or… Read More
Oxford BioMedica Announces Interim Update on ProSavin® Phase I/II Study in Parkinson’s Disease
— Positive review of all patient cohorts by Data Monitoring Committee —— ProSavin® provides long-term improvement of motor function —… Read More
Oxford BioMedica Interim Management Statement November 2011
Oxford, UK – 16 November 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 15 November 2011. Read More
Oxford BioMedica Announces Research and Development Collaboration for Glaucoma
— Research and development agreement signed with Mayo Clinic — Oxford, UK – 31 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
— Third ocular product partnered with Sanofi approved to enter clinical development — Oxford, UK – 18 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford BioMedica plc Interim Results for the Six Months Ended 30 June 2011
Click here to download the full 2011 interim results statement.Click here to download the 2011 interim results slide deck. Read More
Oxford BioMedica Announces Interim Data from Highest (5x) Dose Cohort in ProSavin® Phase I/II Study in Parkinson’s Disease
— Positive interim review of fourth patient cohort by Data Monitoring Committee — Oxford, UK – 4 August 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading… Read More
Oxford BioMedica Announces Ocular Programme Update
— RetinoStat® Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford, UK – 22 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy… Read More
Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
— ‘In vivo’ diagnostic rights granted for cancer imaging — Oxford, UK – 7 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the… Read More
Oxford BioMedica Plc Management and Board Changes
–Oxford BioMedica Appoints Alex Lewis as Director of Corporate Activities and Strategy– Oxford, UK – 24 May 2011: Oxford BioMedica (LSE:OXB), a leading… Read More
Oxford BioMedica Announces Presentation Of New Clinical Data From ProSavin® Phase I/II Study in Parkinson’s Disease
— Six-month data from third cohort presented at ASGCT 14th Annual Meeting —— Highest efficacy results to date with 43% average motor function improvement —… Read More
Oxford BioMedica Interim Management Statement May 2011
Oxford, UK – 18 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene therapy company, today publishes its interim management statement for the period from 1 January to 17 May 2011. Read More